Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review
Head & Neck · 2026-09 · 48 (9) · 2570-2583
DOI: 10.1002/hed.70368 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Head & Neck, online erschienen am 22.06.2026. Verfasst von Nicholas Brian Shannon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Illawarra Shoalhaven Local Health District, Wollongong Hospital, Wollongong, New South Wales, Australia. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients experiencing recurrence. The integration of immune checkpoint inhibitors (ICIs) into the neoadjuvant window represents a paradigm shift toward biologically adapted surgical intervention.
Results
Neoadjuvant immunotherapy capitalizes on an intact immune substrate to create an in situ vaccine, avoiding the post‐surgical immune desert that limits adjuvant efficacy. Emerging phase III data confirm that perioperative ICI significantly improves event‐free survival. Successful implementation requires the surgeon to navigate unique diagnostic challenges, such as distinguishing rare but anatomically risky pseudoprogression from true progression. While combination therapies (chemoimmunotherapy or immunoradiotherapy) yield higher pathologic complete response rates, they also increase toxicity. Intraoperatively, ICI monotherapy generally preserves tissue planes without increasing surgical delays or major wound complications. Standard biomarkers like PD‐L1 and TMB, alongside emerging tools such as liquid biopsy (ctDNA), are essential for patient selection and dynamic monitoring.
Conclusions
The transition to neoadjuvant immunotherapy facilitates future surgical de‐escalation and function‐preserving approaches. To optimize outcomes, the modern surgeon must act as a surgical immunologist, interpreting translational data to guide real‐time operative planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, Illawarra Shoalhaven Local Health District, Wollongong Hospital, Wollongong, New South Wales, Australia.
- Department of Head and Neck Surgery, National Cancer Centre Singapore, Singapore, Singapore.
- Department of Head and Neck Surgery, Singapore General Hospital, Singapore, Singapore.
- Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
ORCID-Profile: Nicholas Brian Shannon, Bruce Ashford
Zitieren
APA
Shannon, N. B., & Ashford, B. (2026). Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review. Head & Neck, 48(9), 2570-2583. https://doi.org/10.1002/hed.70368
Vancouver
Shannon NB, Ashford B. Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review. Head & Neck. 2026;48(9):2570-2583. doi:10.1002/hed.70368
BibTeX
@article{Shannon2026,
author = {Shannon, Nicholas Brian and Ashford, Bruce},
title = {Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review},
journal = {Head & Neck},
year = {2026},
volume = {48},
number = {9},
pages = {2570--2583},
doi = {10.1002/hed.70368}
}
EUVIMED